Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

May 31, 2022

Study Completion Date

September 30, 2022

Conditions
Chronic Hepatitis c
Interventions
DIAGNOSTIC_TEST

lipid profile

Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)

DIAGNOSTIC_TEST

fasting insulin

serum samples used for doing the test by ELISA after fasting for 8 h

DIAGNOSTIC_TEST

fibro scan

liver stiffness by fibro scan before and after treatment

Trial Locations (1)

71515

Assiut University hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03612973 - Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy | Biotech Hunter | Biotech Hunter